Ultragenyx Pharmaceutical Inc. (RARE) 10-Year Financial Performance & Capital Metrics

RARE • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.Show more

Revenue $560M +29.0%
EBITDA -$500M +7.9%
Net Income -$569M +6.2%
EPS (Diluted) -6.29 +23.8%
Gross Margin 86.3% -3.7%
EBITDA Margin -89.33% +28.6%
Operating Margin -95.67% +27.0%
Net Margin -101.6% +27.3%
ROE -211.71% -9.6%
ROIC -343.71% -43.4%
Debt/Equity 0.15 -1.9%
Interest Coverage -8.50 +1.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 40.1%

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 23.1% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y40.12%

3Y16.82%

TTM20.63%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.73%

EPS CAGR

10Y-

5Y-

3Y-

TTM8.22%

ROCE

10Y Avg-47.56%

5Y Avg-38.38%

3Y Avg-46.77%

Latest-45.23%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.46B	291.79	97.26	473.02%	53.3%	17.48%	1.41%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.77B	56.08	25.38	17.97%	16.82%	8.59%	4.41%	0.11
SRPTSarepta Therapeutics, Inc.	2.39B	22.80	9.74	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.32B	24.07	-3.83	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.45	-5.18			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.59B	28.93	-7.09	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.59B	35.41	-7.73	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.28B	42.46	-9.69		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	133K	2.61M	51.49M	103.71M	271.03M	351.41M	363.33M	434.25M	560.23M
Revenue Growth %	-	-	18.64%	18.71%	1.01%	1.61%	0.3%	0.03%	0.2%	0.29%
Cost of Goods Sold+	1.38M	183.2M	1K	1.15M	9.01M	6.13M	16.01M	28.32M	45.21M	76.73M
COGS % of Revenue	-	1377.47%	0%	0.02%	0.09%	0.02%	0.05%	0.08%	0.1%	0.14%
Gross Profit+	-1.38M	-183.07M	2.61M	50.35M	94.71M	264.9M	335.4M	335.01M	389.04M	483.5M
Gross Margin %	-	-1376.47%	1%	0.98%	0.91%	0.98%	0.95%	0.92%	0.9%	0.86%
Gross Profit Growth %	-	-131.28%	1.01%	18.28%	0.88%	1.8%	0.27%	-0%	0.16%	0.24%
Operating Expenses+	147.74M	248.14M	331.55M	421.72M	518.88M	595.02M	717.13M	983.93M	958.25M	1.02B
OpEx % of Revenue	-	1865.71%	126.93%	8.19%	5%	2.2%	2.04%	2.71%	2.21%	1.82%
Selling, General & Admin	33M	64.94M	99.91M	127.72M	161.52M	182.93M	219.98M	278.14M	309.8M	321.61M
SG&A % of Revenue	-	488.24%	38.25%	2.48%	1.56%	0.67%	0.63%	0.77%	0.71%	0.57%
Research & Development	114.74M	183.2M	231.64M	294M	357.36M	412.08M	497.15M	705.79M	648.45M	697.87M
R&D % of Revenue	-	1377.47%	88.68%	5.71%	3.45%	1.52%	1.41%	1.94%	1.49%	1.25%
Other Operating Expenses	-200K	2.17M	0	3.95M	0	0	0	0	0	0
Operating Income+	-147.74M	-248.01M	-328.94M	-371.37M	-424.17M	-330.12M	-381.74M	-648.92M	-569.21M	-535.97M
Operating Margin %	-	-1864.71%	-125.93%	-7.21%	-4.09%	-1.22%	-1.09%	-1.79%	-1.31%	-0.96%
Operating Income Growth %	-1.6%	-0.68%	-0.33%	-0.13%	-0.14%	0.22%	-0.16%	-0.7%	0.12%	0.06%
EBITDA+	-146.35M	-244.58M	-323.12M	-351.83M	-415.63M	-317.86M	-368.5M	-630.7M	-543.2M	-500.43M
EBITDA Margin %	-	-1838.97%	-123.7%	-6.83%	-4.01%	-1.17%	-1.05%	-1.74%	-1.25%	-0.89%
EBITDA Growth %	-1.61%	-0.67%	-0.32%	-0.09%	-0.18%	0.24%	-0.16%	-0.71%	0.14%	0.08%
D&A (Non-Cash Add-back)	1.38M	3.42M	5.83M	19.54M	8.54M	12.26M	13.24M	18.22M	26.01M	35.54M
EBIT	-147.74M	-248.01M	-318.34M	-197.1M	-398.31M	-152.07M	-423.56M	-658.71M	-542.46M	-504.55M
Net Interest Income+	0	3.79M	4.07M	9.54M	12.1M	-26.25M	-27.49M	-31.94M	-39.32M	-26.54M
Interest Income	2.32M	3.79M	4.07M	9.54M	13.24M	7.04M	1.93M	11.07M	26.69M	36.51M
Interest Expense	0	0	0	0	1.14M	33.29M	29.42M	43.02M	66M	63.04M
Other Income/Expense	2.12M	2.17M	10.6M	174.28M	24.73M	144.76M	-71.24M	-52.81M	-39.26M	-31.61M
Pretax Income+	-145.62M	-245.84M	-318.34M	-197.1M	-399.44M	-185.36M	-452.98M	-701.73M	-608.46M	-567.59M
Pretax Margin %	-	-1848.41%	-121.88%	-3.83%	-3.85%	-0.68%	-1.29%	-1.93%	-1.4%	-1.01%
Income Tax+	0	35K	-16.2M	514K	3.28M	1.21M	1.04M	5.7M	-1.82M	1.6M
Effective Tax Rate %	1%	1%	0.95%	1%	1.01%	1.01%	1%	1.01%	1%	1%
Net Income+	-145.62M	-245.87M	-302.14M	-197.61M	-402.73M	-186.57M	-454.02M	-707.42M	-606.64M	-569.18M
Net Margin %	-	-1848.68%	-115.67%	-3.84%	-3.88%	-0.69%	-1.29%	-1.95%	-1.4%	-1.02%
Net Income Growth %	-1.44%	-0.69%	-0.23%	0.35%	-1.04%	0.54%	-1.43%	-0.56%	0.14%	0.06%
Net Income (Continuing)	-145.62M	-245.87M	-302.14M	-197.61M	-402.73M	-186.57M	-454.02M	-707.42M	-606.64M	-569.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	7M
EPS (Diluted)+	-3.96	-6.21	-7.12	-3.97	-7.12	-3.07	-6.70	-10.12	-8.25	-6.29
EPS Growth %	-0.9%	-0.57%	-0.15%	0.44%	-0.79%	0.57%	-1.18%	-0.51%	0.18%	0.24%
EPS (Basic)	-3.96	-6.21	-7.12	-3.97	-7.12	-3.07	-6.70	-10.12	-8.25	-6.29
Diluted Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.8M	69.91M	73.54M	90.54M
Basic Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.8M	69.91M	73.54M	90.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	450.21M	498.11M	244.47M	522.37M	851.02M	1.3B	856.6M	883.9M	732.18M	817.12M
Cash & Short-Term Investments	437M	498.11M	244.47M	459.71M	755.23M	1.2B	740.2M	747.76M	577.21M	610.02M
Cash Only	93.57M	161.12M	100.49M	113.43M	433.58M	713.53M	307.58M	132.94M	213.58M	173.73M
Short-Term Investments	343.43M	219.03M	134M	346.27M	321.65M	488.01M	432.61M	614.82M	363.63M	436.3M
Accounts Receivable	0	0	5.17M	12.74M	32.84M	23.09M	28.43M	40.45M	73.39M	121.8M
Days Sales Outstanding	-	-	722.73	90.3	115.59	31.1	29.53	40.63	61.69	79.36
Inventory	0	0	757K	7.07M	11.55M	13.05M	16.23M	26.77M	33.97M	45.01M
Days Inventory Outstanding	-	-	276.31K	2.25K	467.84	777.05	370.08	344.97	274.25	214.1
Other Current Assets	150K	1.41M	0	0	0	0	0	68.93M	47.62M	40.29M
Total Non-Current Assets+	109.36M	42.52M	246.28M	197.19M	284.48M	464.25M	665.79M	661.54M	758.83M	686.33M
Property, Plant & Equipment	7.37M	17.05M	21.84M	20.05M	74.68M	114.04M	176.18M	259.73M	290.57M	265.93M
Fixed Asset Turnover	-	0.01x	0.12x	2.57x	1.39x	2.38x	1.99x	1.40x	1.49x	2.11x
Goodwill	0	0	44.41M	44.41M	44.41M	44.41M	44.41M	44.41M	44.41M	44.41M
Intangible Assets	0	0	141.54M	129.22M	129M	131.11M	130.79M	160.1M	166.27M	178.31M
Long-Term Investments	99.26M	117.96M	9.97M	1.82M	32.93M	165.88M	293.86M	148.97M	199.9M	135M
Other Non-Current Assets	2.73M	-92.5M	3.41M	3.51M	3.47M	8.81M	20.56M	48.34M	57.69M	62.68M
Total Assets+	559.57M	540.63M	490.75M	719.56M	1.14B	1.76B	1.52B	1.55B	1.49B	1.5B
Asset Turnover	-	0.00x	0.01x	0.07x	0.09x	0.15x	0.23x	0.24x	0.29x	0.37x
Asset Growth %	1.83%	-0.03%	-0.09%	0.47%	0.58%	0.55%	-0.13%	0.02%	-0.04%	0.01%
Total Current Liabilities+	27.92M	60.26M	71.01M	74.72M	103.3M	189.61M	181.37M	261.21M	280.44M	344.15M
Accounts Payable	2.94M	5.36M	8.89M	12.28M	12.87M	12.92M	17.14M	43.27M	42.11M	38.76M
Days Payables Outstanding	775.89	10.69	1000K	3.91K	521.53	769.6	390.77	557.73	340.01	184.36
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	0	0	1000K	1000K	1000K	0	0
Other Current Liabilities	15.55M	37.67M	0	0	0	0	0	0	142.79M	87.47M
Current Ratio	16.13x	8.27x	3.44x	6.99x	8.24x	6.83x	4.72x	3.38x	2.61x	2.37x
Quick Ratio	16.13x	8.27x	3.43x	6.90x	8.13x	6.76x	4.63x	3.28x	2.49x	2.24x
Cash Conversion Cycle	-	-	-1000K	-1.57K	61.9	38.54	8.85	-172.13	-4.07	109.09
Total Non-Current Liabilities+	561K	6.39M	36.28M	35.92M	378.43M	415.57M	418.47M	931.74M	935.16M	897.01M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	29.76M	39.25M	30.9M	19.81M	30.57M	30.04M
Deferred Tax Liabilities	0	0	31.17M	31.17M	33.31M	33.31M	33.31M	31.67M	0	30.06M
Other Non-Current Liabilities	561K	6.39M	5.12M	4.76M	315.37M	335.67M	352.79M	880.26M	904.59M	836.91M
Total Liabilities	28.48M	66.65M	107.3M	110.65M	481.73M	605.18M	599.84M	1.19B	1.22B	1.24B
Total Debt+	0	0	0	0	36.99M	48.23M	41.97M	31.59M	43.17M	40.34M
Net Debt	-93.57M	-161.12M	-100.49M	-113.43M	-396.59M	-665.3M	-265.61M	-101.35M	-170.41M	-133.39M
Debt / Equity	-	-	-	-	0.06x	0.04x	0.05x	0.09x	0.16x	0.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-373.72x	-9.92x	-12.97x	-15.09x	-8.62x	-8.50x
Total Equity+	531.09M	473.97M	383.45M	608.91M	653.76M	1.15B	922.56M	352.49M	275.41M	262.3M
Equity Growth %	1.87%	-0.11%	-0.19%	0.59%	0.07%	0.77%	-0.2%	-0.62%	-0.22%	-0.05%
Book Value per Share	14.44	11.97	9.03	12.23	11.56	18.97	13.61	5.04	3.74	2.90
Total Shareholders' Equity	531.09M	473.97M	383.45M	608.91M	653.76M	1.15B	922.56M	352.49M	275.41M	255.3M
Common Stock	39K	41K	44K	51K	58K	67K	69K	70K	82K	92K
Retained Earnings	-284.66M	-530.53M	-832.67M	-1.03B	-1.43B	-1.62B	-2.07B	-2.78B	-3.39B	-3.96B
Treasury Stock	0	0	0	0	0	0	0	0	-432K	-3.59M
Accumulated OCI	-868K	905K	-5.68M	-633K	-147K	689K	-1.4M	-6.57M	647K	-643K
Minority Interest	0	0	0	0	0	0	0	0	0	7M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-105.98M	-160.97M	-253.84M	-290.57M	-345.38M	-132.22M	-338.69M	-380.46M	-474.81M	-414.19M
Operating CF Margin %	-	-1210.34%	-97.18%	-5.64%	-3.33%	-0.49%	-0.96%	-1.05%	-1.09%	-0.74%
Operating CF Growth %	-1.37%	-0.52%	-0.58%	-0.14%	-0.19%	0.62%	-1.56%	-0.12%	-0.25%	0.13%
Net Income	-145.62M	-245.87M	-302.14M	-197.61M	-402.73M	-186.57M	-454.02M	-707.42M	-606.64M	-569.18M
Depreciation & Amortization	1.38M	3.42M	5.83M	19.54M	8.54M	12.26M	13.24M	18.22M	26.01M	35.54M
Stock-Based Compensation	24.88M	48.31M	68.01M	80.11M	82M	85.73M	104.95M	130.38M	135.21M	158.03M
Deferred Taxes	0	6.16M	-16.25M	-167.65M	-18.94M	-169.78M	48.67M	0	-1.62M	0
Other Non-Cash Items	5.64M	700K	10.93M	-156K	1.69M	21.46M	11.71M	118.12M	-12.67M	-52.5M
Working Capital Changes	7.74M	26.3M	-20.23M	-24.79M	-15.94M	104.66M	-63.24M	60.23M	-15.1M	13.92M
Change in Receivables	0	0	-5.17M	-7.58M	-20.1M	9.84M	-5.43M	-12.07M	-22.78M	-33.6M
Change in Inventory	0	0	-757K	-5.28M	-4.45M	-1.35M	-3.12M	-9.7M	-6.93M	-11.21M
Change in Payables	-1.98M	2.5M	3.46M	3.37M	20.65M	29.6M	2.81M	79.84M	2.38M	46.99M
Cash from Investing+	-292.35M	89.92M	56.42M	-33.33M	-13.04M	-179.12M	-195.37M	-291.65M	168M	-17.77M
Capital Expenditures	-4.96M	-10.19M	-2.79M	-4.08M	-24.83M	-43.91M	-73.09M	-116.12M	-44.27M	-7.49M
CapEx % of Revenue	-	76.6%	1.07%	0.08%	0.24%	0.16%	0.21%	0.32%	0.1%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.54M	-1.2M	934K	170.32M	11.79M	-5.55M	-942K	-30.84M	-7.55M	-14.94M
Cash from Financing+	467.57M	138.68M	136.27M	336.85M	679.31M	600.27M	118.55M	501.21M	388.14M	399.24M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	6.44M	59.19M	9.25M	27.83M	324.06M	89.06M	39.61M	501.21M	8.39M	18.26M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-110.93M	-171.16M	-256.64M	-294.64M	-370.21M	-176.13M	-411.79M	-526.59M	-521.57M	-421.68M
FCF Margin %	-	-1286.94%	-98.25%	-5.72%	-3.57%	-0.65%	-1.17%	-1.45%	-1.2%	-0.75%
FCF Growth %	-1.37%	-0.54%	-0.5%	-0.15%	-0.26%	0.52%	-1.34%	-0.28%	0.01%	0.19%
FCF per Share	-3.02	-4.32	-6.05	-5.92	-6.54	-2.89	-6.07	-7.53	-7.09	-4.66
FCF Conversion (FCF/Net Income)	0.73x	0.65x	0.84x	1.47x	0.86x	0.71x	0.75x	0.54x	0.78x	0.73x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.67%	-48.93%	-70.48%	-39.83%	-63.79%	-20.64%	-43.72%	-110.96%	-193.23%	-211.71%
Return on Invested Capital (ROIC)	-37.05%	-49.58%	-82.81%	-71.56%	-84.54%	-66.36%	-49.96%	-107.19%	-239.74%	-343.71%
Gross Margin	-	-137647.37%	99.96%	97.77%	91.31%	97.74%	95.44%	92.21%	89.59%	86.3%
Net Margin	-	-184867.67%	-11567.34%	-383.75%	-388.31%	-68.84%	-129.2%	-194.71%	-139.7%	-101.6%
Debt / Equity	-	-	-	-	0.06x	0.04x	0.05x	0.09x	0.16x	0.15x
Interest Coverage	-	-	-	-	-373.72x	-9.92x	-12.97x	-15.09x	-8.62x	-8.50x
FCF Conversion	0.73x	0.65x	0.84x	1.47x	0.86x	0.71x	0.75x	0.54x	0.78x	0.73x
Revenue Growth	-	-	1863.91%	1871.48%	101.41%	161.32%	29.66%	3.39%	19.52%	29.01%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	180.41M	285.42M
Product Growth	-	-	-	-	-	-	58.20%
Royalty	-	-	-	-	-	182.65M	274.81M
Royalty Growth	-	-	-	-	-	-	50.46%
Collaboration And License	23.47M	504K	89.22M	85M	7.69M	71.18M	-
Collaboration And License Growth	-	-97.85%	17602.38%	-4.73%	-90.96%	826.15%	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
North America	-	-	237.67M	301.11M	281.09M	307.15M	340.46M
North America Growth	-	-	-	26.69%	-6.65%	9.27%	10.85%
Latin America	-	-	-	-	44.71M	77.34M	130.71M
Latin America Growth	-	-	-	-	-	72.98%	69.01%
Europe	5.29M	12.09M	21.32M	26.66M	36.37M	47.53M	80.12M
Europe Growth	-	128.32%	76.40%	25.06%	36.42%	30.70%	68.56%
Asia Pacific	-	-	-	-	-	-	8.93M
Asia Pacific Growth	-	-	-	-	-	-	-
JAPAN	-	-	-	-	1.16M	2.22M	-
JAPAN Growth	-	-	-	-	-	91.56%	-
All Other	863K	5.19M	12.05M	23.64M	-	-	-
All Other Growth	-	501.04%	132.23%	96.21%	-	-	-
UNITED STATES	45.34M	86.44M	-	-	-	-	-
UNITED STATES Growth	-	90.66%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ultragenyx Pharmaceutical Inc. (RARE) reported $630.6M in revenue for fiscal year 2024.

Ultragenyx Pharmaceutical Inc. (RARE) grew revenue by 29.0% over the past year. This is strong growth.

Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $579.8M for fiscal year 2024.

Dividend & Returns

Ultragenyx Pharmaceutical Inc. (RARE) has a return on equity (ROE) of -211.7%. Negative ROE indicates the company is unprofitable.

Ultragenyx Pharmaceutical Inc. (RARE) had negative free cash flow of $451.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ultragenyx Pharmaceutical Inc. (RARE) 10-Year Financial Performance & Capital Metrics

RARE • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $560M +29.0%
EBITDA -$500M +7.9%
Net Income -$569M +6.2%
EPS (Diluted) -6.29 +23.8%
Gross Margin 86.3% -3.7%
EBITDA Margin -89.33% +28.6%
Operating Margin -95.67% +27.0%
Net Margin -101.6% +27.3%
ROE -211.71% -9.6%
ROIC -343.71% -43.4%
Debt/Equity 0.15 -1.9%
Interest Coverage -8.50 +1.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 40.1%

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 23.1% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y40.12%

3Y16.82%

TTM20.63%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.73%

EPS CAGR

10Y-

5Y-

3Y-

TTM8.22%

ROCE

10Y Avg-47.56%

5Y Avg-38.38%

3Y Avg-46.77%

Latest-45.23%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.46B	291.79	97.26	473.02%	53.3%	17.48%	1.41%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.77B	56.08	25.38	17.97%	16.82%	8.59%	4.41%	0.11
SRPTSarepta Therapeutics, Inc.	2.39B	22.80	9.74	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.32B	24.07	-3.83	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.45	-5.18			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.59B	28.93	-7.09	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.59B	35.41	-7.73	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.28B	42.46	-9.69		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	133K	2.61M	51.49M	103.71M	271.03M	351.41M	363.33M	434.25M	560.23M
Revenue Growth %	-	-	18.64%	18.71%	1.01%	1.61%	0.3%	0.03%	0.2%	0.29%
Cost of Goods Sold+	1.38M	183.2M	1K	1.15M	9.01M	6.13M	16.01M	28.32M	45.21M	76.73M
COGS % of Revenue	-	1377.47%	0%	0.02%	0.09%	0.02%	0.05%	0.08%	0.1%	0.14%
Gross Profit+	-1.38M	-183.07M	2.61M	50.35M	94.71M	264.9M	335.4M	335.01M	389.04M	483.5M
Gross Margin %	-	-1376.47%	1%	0.98%	0.91%	0.98%	0.95%	0.92%	0.9%	0.86%
Gross Profit Growth %	-	-131.28%	1.01%	18.28%	0.88%	1.8%	0.27%	-0%	0.16%	0.24%
Operating Expenses+	147.74M	248.14M	331.55M	421.72M	518.88M	595.02M	717.13M	983.93M	958.25M	1.02B
OpEx % of Revenue	-	1865.71%	126.93%	8.19%	5%	2.2%	2.04%	2.71%	2.21%	1.82%
Selling, General & Admin	33M	64.94M	99.91M	127.72M	161.52M	182.93M	219.98M	278.14M	309.8M	321.61M
SG&A % of Revenue	-	488.24%	38.25%	2.48%	1.56%	0.67%	0.63%	0.77%	0.71%	0.57%
Research & Development	114.74M	183.2M	231.64M	294M	357.36M	412.08M	497.15M	705.79M	648.45M	697.87M
R&D % of Revenue	-	1377.47%	88.68%	5.71%	3.45%	1.52%	1.41%	1.94%	1.49%	1.25%
Other Operating Expenses	-200K	2.17M	0	3.95M	0	0	0	0	0	0
Operating Income+	-147.74M	-248.01M	-328.94M	-371.37M	-424.17M	-330.12M	-381.74M	-648.92M	-569.21M	-535.97M
Operating Margin %	-	-1864.71%	-125.93%	-7.21%	-4.09%	-1.22%	-1.09%	-1.79%	-1.31%	-0.96%
Operating Income Growth %	-1.6%	-0.68%	-0.33%	-0.13%	-0.14%	0.22%	-0.16%	-0.7%	0.12%	0.06%
EBITDA+	-146.35M	-244.58M	-323.12M	-351.83M	-415.63M	-317.86M	-368.5M	-630.7M	-543.2M	-500.43M
EBITDA Margin %	-	-1838.97%	-123.7%	-6.83%	-4.01%	-1.17%	-1.05%	-1.74%	-1.25%	-0.89%
EBITDA Growth %	-1.61%	-0.67%	-0.32%	-0.09%	-0.18%	0.24%	-0.16%	-0.71%	0.14%	0.08%
D&A (Non-Cash Add-back)	1.38M	3.42M	5.83M	19.54M	8.54M	12.26M	13.24M	18.22M	26.01M	35.54M
EBIT	-147.74M	-248.01M	-318.34M	-197.1M	-398.31M	-152.07M	-423.56M	-658.71M	-542.46M	-504.55M
Net Interest Income+	0	3.79M	4.07M	9.54M	12.1M	-26.25M	-27.49M	-31.94M	-39.32M	-26.54M
Interest Income	2.32M	3.79M	4.07M	9.54M	13.24M	7.04M	1.93M	11.07M	26.69M	36.51M
Interest Expense	0	0	0	0	1.14M	33.29M	29.42M	43.02M	66M	63.04M
Other Income/Expense	2.12M	2.17M	10.6M	174.28M	24.73M	144.76M	-71.24M	-52.81M	-39.26M	-31.61M
Pretax Income+	-145.62M	-245.84M	-318.34M	-197.1M	-399.44M	-185.36M	-452.98M	-701.73M	-608.46M	-567.59M
Pretax Margin %	-	-1848.41%	-121.88%	-3.83%	-3.85%	-0.68%	-1.29%	-1.93%	-1.4%	-1.01%
Income Tax+	0	35K	-16.2M	514K	3.28M	1.21M	1.04M	5.7M	-1.82M	1.6M
Effective Tax Rate %	1%	1%	0.95%	1%	1.01%	1.01%	1%	1.01%	1%	1%
Net Income+	-145.62M	-245.87M	-302.14M	-197.61M	-402.73M	-186.57M	-454.02M	-707.42M	-606.64M	-569.18M
Net Margin %	-	-1848.68%	-115.67%	-3.84%	-3.88%	-0.69%	-1.29%	-1.95%	-1.4%	-1.02%
Net Income Growth %	-1.44%	-0.69%	-0.23%	0.35%	-1.04%	0.54%	-1.43%	-0.56%	0.14%	0.06%
Net Income (Continuing)	-145.62M	-245.87M	-302.14M	-197.61M	-402.73M	-186.57M	-454.02M	-707.42M	-606.64M	-569.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	7M
EPS (Diluted)+	-3.96	-6.21	-7.12	-3.97	-7.12	-3.07	-6.70	-10.12	-8.25	-6.29
EPS Growth %	-0.9%	-0.57%	-0.15%	0.44%	-0.79%	0.57%	-1.18%	-0.51%	0.18%	0.24%
EPS (Basic)	-3.96	-6.21	-7.12	-3.97	-7.12	-3.07	-6.70	-10.12	-8.25	-6.29
Diluted Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.8M	69.91M	73.54M	90.54M
Basic Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.8M	69.91M	73.54M	90.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	450.21M	498.11M	244.47M	522.37M	851.02M	1.3B	856.6M	883.9M	732.18M	817.12M
Cash & Short-Term Investments	437M	498.11M	244.47M	459.71M	755.23M	1.2B	740.2M	747.76M	577.21M	610.02M
Cash Only	93.57M	161.12M	100.49M	113.43M	433.58M	713.53M	307.58M	132.94M	213.58M	173.73M
Short-Term Investments	343.43M	219.03M	134M	346.27M	321.65M	488.01M	432.61M	614.82M	363.63M	436.3M
Accounts Receivable	0	0	5.17M	12.74M	32.84M	23.09M	28.43M	40.45M	73.39M	121.8M
Days Sales Outstanding	-	-	722.73	90.3	115.59	31.1	29.53	40.63	61.69	79.36
Inventory	0	0	757K	7.07M	11.55M	13.05M	16.23M	26.77M	33.97M	45.01M
Days Inventory Outstanding	-	-	276.31K	2.25K	467.84	777.05	370.08	344.97	274.25	214.1
Other Current Assets	150K	1.41M	0	0	0	0	0	68.93M	47.62M	40.29M
Total Non-Current Assets+	109.36M	42.52M	246.28M	197.19M	284.48M	464.25M	665.79M	661.54M	758.83M	686.33M
Property, Plant & Equipment	7.37M	17.05M	21.84M	20.05M	74.68M	114.04M	176.18M	259.73M	290.57M	265.93M
Fixed Asset Turnover	-	0.01x	0.12x	2.57x	1.39x	2.38x	1.99x	1.40x	1.49x	2.11x
Goodwill	0	0	44.41M	44.41M	44.41M	44.41M	44.41M	44.41M	44.41M	44.41M
Intangible Assets	0	0	141.54M	129.22M	129M	131.11M	130.79M	160.1M	166.27M	178.31M
Long-Term Investments	99.26M	117.96M	9.97M	1.82M	32.93M	165.88M	293.86M	148.97M	199.9M	135M
Other Non-Current Assets	2.73M	-92.5M	3.41M	3.51M	3.47M	8.81M	20.56M	48.34M	57.69M	62.68M
Total Assets+	559.57M	540.63M	490.75M	719.56M	1.14B	1.76B	1.52B	1.55B	1.49B	1.5B
Asset Turnover	-	0.00x	0.01x	0.07x	0.09x	0.15x	0.23x	0.24x	0.29x	0.37x
Asset Growth %	1.83%	-0.03%	-0.09%	0.47%	0.58%	0.55%	-0.13%	0.02%	-0.04%	0.01%
Total Current Liabilities+	27.92M	60.26M	71.01M	74.72M	103.3M	189.61M	181.37M	261.21M	280.44M	344.15M
Accounts Payable	2.94M	5.36M	8.89M	12.28M	12.87M	12.92M	17.14M	43.27M	42.11M	38.76M
Days Payables Outstanding	775.89	10.69	1000K	3.91K	521.53	769.6	390.77	557.73	340.01	184.36
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	0	0	1000K	1000K	1000K	0	0
Other Current Liabilities	15.55M	37.67M	0	0	0	0	0	0	142.79M	87.47M
Current Ratio	16.13x	8.27x	3.44x	6.99x	8.24x	6.83x	4.72x	3.38x	2.61x	2.37x
Quick Ratio	16.13x	8.27x	3.43x	6.90x	8.13x	6.76x	4.63x	3.28x	2.49x	2.24x
Cash Conversion Cycle	-	-	-1000K	-1.57K	61.9	38.54	8.85	-172.13	-4.07	109.09
Total Non-Current Liabilities+	561K	6.39M	36.28M	35.92M	378.43M	415.57M	418.47M	931.74M	935.16M	897.01M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	29.76M	39.25M	30.9M	19.81M	30.57M	30.04M
Deferred Tax Liabilities	0	0	31.17M	31.17M	33.31M	33.31M	33.31M	31.67M	0	30.06M
Other Non-Current Liabilities	561K	6.39M	5.12M	4.76M	315.37M	335.67M	352.79M	880.26M	904.59M	836.91M
Total Liabilities	28.48M	66.65M	107.3M	110.65M	481.73M	605.18M	599.84M	1.19B	1.22B	1.24B
Total Debt+	0	0	0	0	36.99M	48.23M	41.97M	31.59M	43.17M	40.34M
Net Debt	-93.57M	-161.12M	-100.49M	-113.43M	-396.59M	-665.3M	-265.61M	-101.35M	-170.41M	-133.39M
Debt / Equity	-	-	-	-	0.06x	0.04x	0.05x	0.09x	0.16x	0.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-373.72x	-9.92x	-12.97x	-15.09x	-8.62x	-8.50x
Total Equity+	531.09M	473.97M	383.45M	608.91M	653.76M	1.15B	922.56M	352.49M	275.41M	262.3M
Equity Growth %	1.87%	-0.11%	-0.19%	0.59%	0.07%	0.77%	-0.2%	-0.62%	-0.22%	-0.05%
Book Value per Share	14.44	11.97	9.03	12.23	11.56	18.97	13.61	5.04	3.74	2.90
Total Shareholders' Equity	531.09M	473.97M	383.45M	608.91M	653.76M	1.15B	922.56M	352.49M	275.41M	255.3M
Common Stock	39K	41K	44K	51K	58K	67K	69K	70K	82K	92K
Retained Earnings	-284.66M	-530.53M	-832.67M	-1.03B	-1.43B	-1.62B	-2.07B	-2.78B	-3.39B	-3.96B
Treasury Stock	0	0	0	0	0	0	0	0	-432K	-3.59M
Accumulated OCI	-868K	905K	-5.68M	-633K	-147K	689K	-1.4M	-6.57M	647K	-643K
Minority Interest	0	0	0	0	0	0	0	0	0	7M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-105.98M	-160.97M	-253.84M	-290.57M	-345.38M	-132.22M	-338.69M	-380.46M	-474.81M	-414.19M
Operating CF Margin %	-	-1210.34%	-97.18%	-5.64%	-3.33%	-0.49%	-0.96%	-1.05%	-1.09%	-0.74%
Operating CF Growth %	-1.37%	-0.52%	-0.58%	-0.14%	-0.19%	0.62%	-1.56%	-0.12%	-0.25%	0.13%
Net Income	-145.62M	-245.87M	-302.14M	-197.61M	-402.73M	-186.57M	-454.02M	-707.42M	-606.64M	-569.18M
Depreciation & Amortization	1.38M	3.42M	5.83M	19.54M	8.54M	12.26M	13.24M	18.22M	26.01M	35.54M
Stock-Based Compensation	24.88M	48.31M	68.01M	80.11M	82M	85.73M	104.95M	130.38M	135.21M	158.03M
Deferred Taxes	0	6.16M	-16.25M	-167.65M	-18.94M	-169.78M	48.67M	0	-1.62M	0
Other Non-Cash Items	5.64M	700K	10.93M	-156K	1.69M	21.46M	11.71M	118.12M	-12.67M	-52.5M
Working Capital Changes	7.74M	26.3M	-20.23M	-24.79M	-15.94M	104.66M	-63.24M	60.23M	-15.1M	13.92M
Change in Receivables	0	0	-5.17M	-7.58M	-20.1M	9.84M	-5.43M	-12.07M	-22.78M	-33.6M
Change in Inventory	0	0	-757K	-5.28M	-4.45M	-1.35M	-3.12M	-9.7M	-6.93M	-11.21M
Change in Payables	-1.98M	2.5M	3.46M	3.37M	20.65M	29.6M	2.81M	79.84M	2.38M	46.99M
Cash from Investing+	-292.35M	89.92M	56.42M	-33.33M	-13.04M	-179.12M	-195.37M	-291.65M	168M	-17.77M
Capital Expenditures	-4.96M	-10.19M	-2.79M	-4.08M	-24.83M	-43.91M	-73.09M	-116.12M	-44.27M	-7.49M
CapEx % of Revenue	-	76.6%	1.07%	0.08%	0.24%	0.16%	0.21%	0.32%	0.1%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.54M	-1.2M	934K	170.32M	11.79M	-5.55M	-942K	-30.84M	-7.55M	-14.94M
Cash from Financing+	467.57M	138.68M	136.27M	336.85M	679.31M	600.27M	118.55M	501.21M	388.14M	399.24M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	6.44M	59.19M	9.25M	27.83M	324.06M	89.06M	39.61M	501.21M	8.39M	18.26M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-110.93M	-171.16M	-256.64M	-294.64M	-370.21M	-176.13M	-411.79M	-526.59M	-521.57M	-421.68M
FCF Margin %	-	-1286.94%	-98.25%	-5.72%	-3.57%	-0.65%	-1.17%	-1.45%	-1.2%	-0.75%
FCF Growth %	-1.37%	-0.54%	-0.5%	-0.15%	-0.26%	0.52%	-1.34%	-0.28%	0.01%	0.19%
FCF per Share	-3.02	-4.32	-6.05	-5.92	-6.54	-2.89	-6.07	-7.53	-7.09	-4.66
FCF Conversion (FCF/Net Income)	0.73x	0.65x	0.84x	1.47x	0.86x	0.71x	0.75x	0.54x	0.78x	0.73x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.67%	-48.93%	-70.48%	-39.83%	-63.79%	-20.64%	-43.72%	-110.96%	-193.23%	-211.71%
Return on Invested Capital (ROIC)	-37.05%	-49.58%	-82.81%	-71.56%	-84.54%	-66.36%	-49.96%	-107.19%	-239.74%	-343.71%
Gross Margin	-	-137647.37%	99.96%	97.77%	91.31%	97.74%	95.44%	92.21%	89.59%	86.3%
Net Margin	-	-184867.67%	-11567.34%	-383.75%	-388.31%	-68.84%	-129.2%	-194.71%	-139.7%	-101.6%
Debt / Equity	-	-	-	-	0.06x	0.04x	0.05x	0.09x	0.16x	0.15x
Interest Coverage	-	-	-	-	-373.72x	-9.92x	-12.97x	-15.09x	-8.62x	-8.50x
FCF Conversion	0.73x	0.65x	0.84x	1.47x	0.86x	0.71x	0.75x	0.54x	0.78x	0.73x
Revenue Growth	-	-	1863.91%	1871.48%	101.41%	161.32%	29.66%	3.39%	19.52%	29.01%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	180.41M	285.42M
Product Growth	-	-	-	-	-	-	58.20%
Royalty	-	-	-	-	-	182.65M	274.81M
Royalty Growth	-	-	-	-	-	-	50.46%
Collaboration And License	23.47M	504K	89.22M	85M	7.69M	71.18M	-
Collaboration And License Growth	-	-97.85%	17602.38%	-4.73%	-90.96%	826.15%	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
North America	-	-	237.67M	301.11M	281.09M	307.15M	340.46M
North America Growth	-	-	-	26.69%	-6.65%	9.27%	10.85%
Latin America	-	-	-	-	44.71M	77.34M	130.71M
Latin America Growth	-	-	-	-	-	72.98%	69.01%
Europe	5.29M	12.09M	21.32M	26.66M	36.37M	47.53M	80.12M
Europe Growth	-	128.32%	76.40%	25.06%	36.42%	30.70%	68.56%
Asia Pacific	-	-	-	-	-	-	8.93M
Asia Pacific Growth	-	-	-	-	-	-	-
JAPAN	-	-	-	-	1.16M	2.22M	-
JAPAN Growth	-	-	-	-	-	91.56%	-
All Other	863K	5.19M	12.05M	23.64M	-	-	-
All Other Growth	-	501.04%	132.23%	96.21%	-	-	-
UNITED STATES	45.34M	86.44M	-	-	-	-	-
UNITED STATES Growth	-	90.66%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ultragenyx Pharmaceutical Inc. (RARE) reported $630.6M in revenue for fiscal year 2024.

Ultragenyx Pharmaceutical Inc. (RARE) grew revenue by 29.0% over the past year. This is strong growth.

Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $579.8M for fiscal year 2024.

Dividend & Returns

Ultragenyx Pharmaceutical Inc. (RARE) has a return on equity (ROE) of -211.7%. Negative ROE indicates the company is unprofitable.

Ultragenyx Pharmaceutical Inc. (RARE) had negative free cash flow of $451.4M in fiscal year 2024, likely due to heavy capital investments.